[SIGNIFICANCE OF INTRADUCTAL CARCINOMA OF THE PROSTATE IN POST-OPERATIVE BIOCHEMICAL RECURRENCE].

(Objective) We investigated the prognostic significance of intraductal carcinoma of the prostate (IDC-P) in radical prostatectomy specimens. (Materials and methods) We evaluated 441 patients treated with radical prostatectomy and analyzed data on IDC-P, lymph node metastases, Gleason score, seminal vesicle invasion, extraprostatic extension, surgical margin, total cancer volume, and zonal origin of dominant cancer focus in radical prostatectomy specimens. The median follow-up was 50 months (range 6-164 months). (Results) We identified IDC-P in 112 cases (25.4%). The five-year biochemical progression-free survival rate in patients with IDC-P was significantly lower than for those without IDC-P (35.8% vs 69.6%; p<0.0001). In a univariate analysis, IDC-P (p<0.0001), lymph node metastases (p=0.0022), Gleason score (p<0.0001), seminal vesicle invasion (p<0.0001), extraprostatic extension (p<0.0001), surgical margin (p<0.0001) and total cancer volume (p<0.0001) were significantly associated with the biochemical progression-free survival. In a multivariate analysis, Gleason score (p<0.0001), IDC-P (p=0.0002), seminal vesicle invasion (p=0.0011), extraprostatic extension (p=0.0012), surgical margin (p=0.0019) and lymph node metastases (p=0.0402) were significantly associated with biochemical progression-free survival. (Conclusions) The presence of IDC-P is an independent factor of biochemical recurrence in prostate cancer patients treated with radical prostatectomy. We therefore recommend that the presence of IDC-P in radical prostatectomy specimens be reported.

[1]  Y. Horiguchi,et al.  Prediction of biochemical recurrence after robot‐assisted radical prostatectomy: Analysis of 784 Japanese patients , 2015, International journal of urology : official journal of the Japanese Urological Association.

[2]  T. Tsuzuki,et al.  Prognostic value of intraductal carcinoma of the prostate in radical prostatectomy specimens , 2014, The Prostate.

[3]  B. Miles,et al.  Heterogeneous clinicopathological features of intraductal carcinoma of the prostate: a comparison between "precursor-like" and "regular type" lesions. , 2014, International journal of clinical and experimental pathology.

[4]  J. Hicks,et al.  Cytoplasmic PTEN Protein Loss Distinguishes Intraductal Carcinoma of the Prostate from High Grade Prostatic Intraepithelial Neoplasia , 2012, Modern Pathology.

[5]  T. H. van der Kwast,et al.  Biopsy diagnosis of intraductal carcinoma is prognostic in intermediate and high risk prostate cancer patients treated by radiotherapy. , 2012, European journal of cancer.

[6]  Jianfeng Xu,et al.  PTEN Protein Loss by Immunostaining: Analytic Validation and Prognostic Indicator for a High Risk Surgical Cohort of Prostate Cancer Patients , 2011, Clinical Cancer Research.

[7]  R. Moorin,et al.  A post‐radical‐prostatectomy nomogram incorporating new pathological variables and interaction terms for improved prognosis , 2011, BJU international.

[8]  M. Menon,et al.  Biochemical recurrence following robot-assisted radical prostatectomy: analysis of 1384 patients with a median 5-year follow-up. , 2010, European urology.

[9]  J. Epstein,et al.  Intraductal carcinoma of the prostate without invasive carcinoma on needle biopsy: emphasis on radical prostatectomy findings. , 2010, Journal of Urology.

[10]  K. Do,et al.  Morphologic characterization of preoperatively treated prostate cancer: toward a post-therapy histologic classification. , 2010, European urology.

[11]  R. Shah,et al.  ETS Gene Aberrations in Atypical Cribriform Lesions of the Prostate: Implications for the Distinction Between Intraductal Carcinoma of the Prostate and Cribriform High-grade Prostatic Intraepithelial Neoplasia , 2010, The American journal of surgical pathology.

[12]  R. Shah,et al.  Atypical Cribriform Lesions of the Prostate: Relationship to Prostatic Carcinoma and Implication for Diagnosis in Prostate Biopsies , 2010, The American journal of surgical pathology.

[13]  R. Shah,et al.  Characterization of TMPRSS2-ETS gene aberrations in androgen-independent metastatic prostate cancer. , 2008, Cancer research.

[14]  L. Klotz,et al.  Expression of TMPRSS2:ERG gene fusion in prostate cancer cells is an important prognostic factor for cancer progression , 2007, Cancer biology & therapy.

[15]  J. Epstein,et al.  Intraductal carcinoma of the prostate on needle biopsy: histologic features and clinical significance , 2006, Modern Pathology.

[16]  P. Karakiewicz,et al.  25-year prostate cancer control and survival outcomes: a 40-year radical prostatectomy single institution series. , 2006, The Journal of urology.

[17]  E. B. Butler,et al.  Salvage radiotherapy for recurrent prostate cancer after radical prostatectomy. , 2004, JAMA.

[18]  Michael W Kattan,et al.  Cancer control with radical prostatectomy alone in 1,000 consecutive patients. , 2002, The Journal of urology.

[19]  J. McNeal,et al.  Patterns of differentiation and proliferation in intraductal carcinoma of the prostate: Significance for cancer progression , 2000, The Prostate.

[20]  P. Scardino,et al.  Patterns of high-grade prostatic intraepithelial neoplasia associated with clinically aggressive prostate cancer. , 1998, Human pathology.

[21]  M. Rubin,et al.  Cribriform carcinoma of the prostate and cribriform prostatic intraepithelial neoplasia: incidence and clinical implications. , 1998, The American journal of surgical pathology.

[22]  J. McNeal,et al.  Spread of adenocarcinoma within prostatic ducts and acini. Morphologic and clinical correlations. , 1996, The American journal of surgical pathology.

[23]  A. Partin,et al.  Morphometric measurement of tumor volume and per cent of gland involvement as predictors of pathological stage in clinical stage B prostate cancer. , 1989, The Journal of urology.

[24]  J. Kovi,et al.  Ductal spread in prostatic carcinoma , 1985, Cancer.